ImmuneRegen BioSciences(R) Initiates Strategic Collaboration With MPI Research to Accelerate Clinical Development of Lead Indica
21 Abril 2010 - 9:00AM
Marketwired
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR
BioSciences Holdings, Inc. (OTCBB: IRBS), entered into a strategic
collaboration with MPI Research today. Under the agreement, MPI
Research will develop and perform preclinical, FDA-required safety
studies and analytical research services in support of
ImmuneRegen's lead drug candidate, Homspera®, which are expected to
enable Phase 1 human clinical studies. Mutually agreeable financial
incentives have been incorporated into the terms of this agreement.
"The signing of today's agreement with MPI Research allows us to
begin our FDA-required safety studies immediately," said
ImmuneRegen CEO Michael Wilhelm. "ImmuneRegen expects that the
resulting studies will provide information necessary to support
planned INDs for indications such as influenza, idiopathic
pulmonary fibrosis, and cancer. With this relationship, ImmuneRegen
garners independent validation that the potential of our compound
has significant value to industry. We feel our visibility to
potential new partners will only increase as we achieve the
significant milestones set forth by our development team. This is a
pivotal time for the company and we believe this relationship
confirms management's belief that our company is significantly
undervalued."
William U. Parfet, MBA, Chairman and CEO of MPI Research, also
recognizes the value this cooperative agreement creates and stated,
"ImmuneRegen and MPI Research are both innovative companies that,
together, create a synergy that is important within today's drug
development industry. This collaboration reflects the flexible,
solution-based mindset of each organization, allowing them to
effectively leverage their respective strengths and resources."
About MPI Research MPI Research, a
preclinical contract research organization with global headquarters
in Mattawan, Michigan, provides discovery, safety evaluation,
bioanalytical, and analytical services to the biopharmaceutical,
medical device, animal health, and chemical industries. Scientific
knowledge and experience, integrity, trust, teamwork, and
dedication to strong and enduring Sponsor relationships are the
defining attributes that characterize MPI Research as a
high-performance, high-quality organization that is committed to
bringing safer and more effective products to the world. Learn more
about how the company can exceed your expectations at
www.mpiresearch.com.
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR
BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage
biotechnology company focused on the research, development and
licensing of Homspera® and its derivatives.
Homspera is an adult stem cell active compound that in study
results has been shown to regenerate and strengthen the immune
system and enhance wound healing. Additional intended uses being
developed include influenza as a stand-alone or combination therapy
and as a vaccine adjuvant. To advance its mission, the Scottsdale,
Arizona based company has forged numerous study partnerships with
industry and academic leaders, including Celgene Cellular
Therapeutics, HemoGenix, Lovelace Respiratory Research Institute
and Virion Systems. For more information, please visit
www.immuneregen.com.
Statements about the Company's future expectations, including
statements about the potential use and scientific results for the
Company's drug candidates, science and technology, and all other
statements in this press release other than historical facts, are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Securities
Litigation Reform Act of 1995. The Company intends that such
forward-looking statements be subject to the safe harbors created
thereby. These future events may not occur as and when expected, if
at all, and, together with the Company's business, are subject to
various risks and uncertainties. The Company's actual results could
differ materially from expected results as a result of a number of
factors, including the uncertainties inherent in research and
development collaborations, pre-clinical and clinical trials and
product development programs (including, but not limited to the
fact that future results or research and development efforts may
prove less encouraging than current results or cause side effects
not observed in current pre-clinical trials), the evaluation of
potential opportunities, the level of corporate expenditures and
monies available for further studies, capital market conditions,
and others set forth in the Company's periodic report on Form 10-Q
for the three months ended September 30, 2009 as filed with the
Securities and Exchange Commission and report on Form 10-K for the
year ended December 31, 2008 as filed with the Securities and
Exchange Commission. There are no guarantees that any of the
Company's proposed products will prove to be commercially
successful. The Company undertakes no duty to update
forward-looking statements.
Contact: Michael K. Wilhelm, email: Email Contact John Fermanis,
email: Email Contact ImmuneRegen BioSciences Inc. Phone:
480-922-3926 Investor Contact: Redwood Consultants, LLC at
415-884-0348
IR BioSciences (CE) (USOTC:IRBS)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
IR BioSciences (CE) (USOTC:IRBS)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024